FDA Approval Milestone: Femasys has received 510(k) clearance from the FDA for its FemVue Controlled device, marking a significant advancement in the fertility and non-surgical permanent birth control sectors, which is expected to enhance market competitiveness.
Technological Integration Innovation: The new device integrates FemVue and FemChec technologies into a single platform, supporting multiple clinical applications while streamlining manufacturing and operational workflows, thereby improving healthcare service efficiency.
Market Potential Expansion: The launch of FemVue Controlled will strengthen Femasys's position in the global fertility treatment market, particularly as non-surgical contraception solutions gain increasing attention, which is expected to attract more customers.
Strategic Development Direction: Femasys is committed to enhancing accessibility and cost-effectiveness of women's health services through innovative product offerings, and the introduction of FemVue Controlled will further propel its commercialization efforts in global markets.
FEMY
$0.7975+Infinity%1D
Analyst Views on FEMY
Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.766
Low
3.00
Averages
5.50
High
8.00
Current: 0.766
Low
3.00
Averages
5.50
High
8.00
Laidlaw
Yale Jen
initiated
$6.50
2025-11-20
Reason
Laidlaw
Yale Jen
Price Target
$6.50
2025-11-20
initiated
Reason
Laidlaw analyst Yale Jen initiated coverage of Femasys with a Buy rating and $6.50 price target. Femasys is a development stage medical technology company focusing on two lead women healthcare products, FemaSeed and FemBloc, the analyst tells investors in a research note. The firm says FemaSeed is exploring a new and large market opportunity via gynecologist channel while FemBloc is heading to pivotal clinical study backed by "robust" prior clinical data.
JonesResearch
Buy
downgrade
$10 -> $6
2025-05-13
Reason
JonesResearch
Price Target
$10 -> $6
2025-05-13
downgrade
Buy
Reason
JonesResearch lowered the firm's price target on Femasys to $6 from $10 and keeps a Buy rating on the shares. The company reported Q1 earnings with no major updates to catalysts or its cash runway, the analyst tells investors in a research note. The firm remains positive on Femasys, but cut its price target to reflect the delayed launch of FemaSeed and an increase in share count from potential financing in 2025.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$15
2025-03-28
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$12 → $15
2025-03-19
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12 → $15
2025-03-19
Maintains
Strong Buy
Reason
About FEMY
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
